A detailed history of Rathbones Group PLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Rathbones Group PLC holds 28,611 shares of VIR stock, worth $247,199. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,611
Previous 28,611 -0.0%
Holding current value
$247,199
Previous $254,000 15.75%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$7.63 - $12.66 $26,369 - $43,752
-3,456 Reduced 10.78%
28,611 $254,000
Q4 2023

Feb 13, 2024

BUY
$7.76 - $10.29 $77,600 - $102,899
10,000 Added 45.32%
32,067 $322,000
Q3 2023

Nov 13, 2023

BUY
$9.14 - $24.62 $100,540 - $270,820
11,000 Added 99.39%
22,067 $206,000
Q4 2021

Feb 10, 2022

BUY
$30.97 - $54.03 $187,894 - $327,800
6,067 Added 121.34%
11,067 $463,000
Q3 2021

Nov 04, 2021

BUY
$34.9 - $54.54 $174,500 - $272,700
5,000 New
5,000 $218,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $1.15B
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Rathbones Group PLC Portfolio

Follow Rathbones Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Rathbones Group PLC with notifications on news.